Literature DB >> 16540949

Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction.

Kazuhiro Nakanishi1, Shinhiro Takeda, Atsuhiro Sakamoto, Akira Kitamura.   

Abstract

OBJECTIVE: To examine the association between decreased release of proinflammatory cytokines in response to urinary trypsin inhibitor pretreatment and decreased myocardial and lung injury after cardiopulmonary bypass.
DESIGN: A prospective, randomized, double-blind study.
SETTING: University hospital.
SUBJECTS: Thirty patients on cardiopulmonary bypass undergoing coronary artery bypass grafting.
INTERVENTIONS: Patients received 5000 units/kg intravenous urinary trypsin inhibitor (n = 15) or 0.9% saline (control, n = 15) immediately before aortic cannulation for cardiopulmonary bypass. MEASUREMENT AND MAIN
RESULTS: Neutrophil elastase, tumor necrosis factor-alpha, interleukin-6, and interleukin-8 were measured after intubation (T1), immediately before aortic cannulation (T2), after separation from cardiopulmonary bypass (T3), at the end of surgery (T4), and on postoperative days 1 (T5), 3 (T6), and 5 (T7). Simultaneous hematocrit values were obtained at all sample times. Isoenzyme of creatine kinase with muscle and brain subunits, troponin-T, and myosin light chain I were also measured. Various hemodynamic and pulmonary data were obtained perioperatively. Levels of neutrophil elastase and cytokines were corrected for hemodilution. Interleukin-6 and interleukin-8 levels were lower at T3 and T4 in the urinary trypsin inhibitor group than in the control group. Stroke volume index was significantly decreased in the control group at T3, and statistical difference was found between groups at T3 (p < .01). Respiratory index and intrapulmonary shunt were significantly higher in the control group than in the urinary trypsin inhibitor group at T3. Changes in respiratory index and intrapulmonary shunt correlated with interleukin-8 levels at T3 (r = .52, p < 00001; r = .37, p < 0001, respectively) and T4 (r = .44, p < .001; r = .24, p < .05, respectively). Neutrophil elastase levels and cardiac marker responses to coronary artery bypass grafting surgery were similar in both groups.
CONCLUSIONS: Prepump administration of urinary trypsin inhibitor attenuates the elevation of interleukin-6 and interleukin-8 release immediately after cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540949     DOI: 10.1097/01.CCM.0000215110.55899.AE

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  24 in total

1.  Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection.

Authors:  Hong Liu; Si-Chong Qian; Yong-Feng Shao; Hai-Yang Li
Journal:  J Inflamm Res       Date:  2022-06-27

2.  Ulinastatin plus biapenem for severe pneumonia in the elderly and its influence on pulmonary function and inflammatory cytokines.

Authors:  Rui Zhang; Jitao Ma; Pengxiao Zheng; Ruirui Zheng; Xu Meng; Yinjia Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass.

Authors:  Se-Young Oh; Jong Chan Kim; Yong Seon Choi; Woo Kyung Lee; Yeong-Kyu Lee; Young Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2012-02-20

4.  Postconditioning improvement effects of ulinastatin on brain injury following cardiopulmonary resuscitation.

Authors:  Bo Sui; Yongwang Li; Li Ma
Journal:  Exp Ther Med       Date:  2014-08-04       Impact factor: 2.447

5.  Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan.

Authors:  Yun Zhang; Zhi Zeng; Yu Cao; Xiaodong Du; Zhi Wan
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

6.  Effects of ulinastatin on postoperative blood loss and hemostasis in atrioventricular valve surgery with cardiopulmonary bypass.

Authors:  Jae Bum Park; Seong Hyop Kim; Song Am Lee; Jin Woo Chung; Jun Seok Kim; Hyun Keun Chee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-06-05

7.  Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery.

Authors:  Na-Young Kim; Jae-Kwang Shim; Seo-Ouk Bang; Jee-Suk Sim; Jong-Wook Song; Young-Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2013-02-15

8.  Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: a randomized double-blinded study.

Authors:  Jieun Song; Jungmin Park; Jee-Young Kim; Joo-Duck Kim; Woon-Seok Kang; Hasmizy Bin Muhammad; Mi-Young Kwon; Seong-Hyop Kim; Tae Gyoon Yoon; Tae-Yop Kim; Jin Woo Chung
Journal:  Korean J Anesthesiol       Date:  2013-04-22

9.  Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway.

Authors:  Bo Xu; Kun-Ping Li; Fei Shen; Huan-Qing Xiao; Wen-Song Cai; Jiang-Lin Li; Qi-Cai Liu; Lin Jia
Journal:  Biomed Res Int       Date:  2013-04-23       Impact factor: 3.411

Review 10.  Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Qiu-Lan He; Fei Zhong; Fang Ye; Ming Wei; Wei-Feng Liu; Mei-Na Li; Qiao-Bo Li; Wen-Qi Huang; Lai-Bao Sun; Hai-Hua Shu
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.